AdipoSeeds

AdipoSeeds is a clinical-stage biotechnology company based in Japan that specializes in the development of regenerative medicine products derived from adipose tissue. The company's core technology involves the generation of induced pluripotent stem cells (iPSCs) from adipose-derived mesenchymal stem cells, which are then differentiated into functional platelets. Their lead program, ASD-001, is an autologous cell therapy designed to treat critical limb ischemia by promoting vascular regeneration. By leveraging the abundance and accessibility of adipose tissue, AdipoSeeds aims to provide scalable and effective cell-based treatments for intractable vascular and hematological diseases. The company is currently advancing its pipeline through clinical trials in Japan, focusing on conditions with high unmet medical needs.